Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
about
Discovery and Characterization of a Highly Potent and Selective Aminopyrazoline-Based in Vivo Probe (BAY-598) for the Protein Lysine Methyltransferase SMYD2Overexpression of denticleless E3 ubiquitin protein ligase homolog (DTL) is related to poor outcome in gastric carcinomaQuantitative Profiling of the Activity of Protein Lysine Methyltransferase SMYD2 Using SILAC-Based ProteomicsCoordination of stress signals by the lysine methyltransferase SMYD2 promotes pancreatic cancer.Expression of histone methyltransferases as novel biomarkers for renal cell tumor diagnosis and prognostication.Smyd2 is a Myc-regulated gene critical for MLL-AF9 induced leukemogenesis.Structure and function of SET and MYND domain-containing proteins.Overexpression of TRIM44 is related to invasive potential and malignant outcomes in esophageal squamous cell carcinoma.Overexpression of PBK/TOPK relates to tumour malignant potential and poor outcome of gastric carcinoma.H3K36 methyltransferases as cancer drug targets: rationale and perspectives for inhibitor developmentTherapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents.Writing, erasing and reading histone lysine methylations.Residual expression of SMYD2 and SMYD3 is associated with the acquisition of complex karyotype in chronic lymphocytic leukemia.SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stressOverexpression of CTEN relates to tumor malignant potential and poor outcomes of adenocarcinoma of the esophagogastric junction.Positive Expression of SMYD2 is Associated with Poor Prognosis in Patients with Primary Hepatocellular Carcinoma.Overexpression of ZRF1 is related to tumor malignant potential and a poor outcome of gastric carcinoma.Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation.
P2860
Q28829391-A0518AF8-149E-4974-81CD-29A77FD082FAQ36546735-D194F317-E721-4B20-93AB-7E4276AD5A69Q36745154-6D824ED4-ABAB-4E60-BE4E-EE7128D069A5Q36783008-4F547A2B-A4CA-43AA-B0FC-DCA3DFE95336Q36833415-7C62EAAF-4749-43D5-90CC-0599B3E7E6C9Q37686995-B244B5C4-EA0B-4A47-B1CC-C0DED1516049Q38314974-2D5C75CF-CA13-4144-ABA3-AEC5F3330E2CQ38700230-7B149683-9845-4361-AFF8-F45F7AF8B92FQ38728416-EF491218-5493-4EC2-BE9D-373EF5431F7EQ38829055-8E869C19-5F92-4CFF-8016-A7E4BCBC4DB3Q39055609-128370D3-3DB4-4390-9632-CBA36E06AD3CQ39268171-1A8220E9-26F9-4AC1-966B-E086BB7C0ACBQ40083143-631D4709-36ED-43C6-9145-FFB990A2B0E3Q42293531-22EFF9C0-D119-461C-ADF5-A1B453A3C1BEQ46011707-1FEBB237-AD27-4DAC-BB76-C5A434CC51F7Q49653999-1C456627-865F-4C73-8446-15C1A49BA0B6Q49935203-241602F4-9F7E-4657-A6E1-E55183BB8C7CQ55129685-FFB34D25-62B9-4E93-9AEF-0E9BBFE12306
P2860
Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
2014年论文
@zh
2014年论文
@zh-cn
name
Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
@ast
Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
@en
type
label
Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
@ast
Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
@en
prefLabel
Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
@ast
Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
@en
P2093
P2860
P356
P1476
Overexpression of SMYD2 contributes to malignant outcome in gastric cancer.
@en
P2093
A Shiozaki
D Ichikawa
H Fujiwara
P2860
P2888
P304
P356
10.1038/BJC.2014.543
P407
P577
2014-10-16T00:00:00Z